4Hawkey PM,Jones AM. The changing epidemiology of resistance[J]. J Antimicrob Chemother,2009,64(1):i3-i10.
5DeRyke CA, Kuti J L, Nicolau DP. Pharmaeodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa , Acinetobacter baumannii , Escherichia coli and Klebsiella species collected from United States intensive care units in 2004[J]. Pharmacotherapy, 2007,27 (3): 333-342.
6Ikawa K , Morikawa N , Ikeda K , et al . Pharmacodynamic as sessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetie modeling and Monte Carlo simulation[J]. Diagn Microbiol Infect Dis, 2008,62(3) : 292-297.
7Wang H, Zhang B, Ni YX, et al. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004[J]. Int J Antimierob Agents, 2007,30(5) :452-457.
8Ludwig E,Konkoly-Thege M,Kuti JL,et al. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals [J]. Antimicrob Agents, 2006,28 ( 5 ) : 433-438.
9DeRyke CA, Kuti J L, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoro- quinolones against Pseudomonas aeruginosa , Acinetobacter baumannii , Escherichia coli and Klebsiella species collected from United States intensive care units in 2004[J]. Pharmacotherapy,2007, 27(3):333--342.
10Ikawa K, Morikawa N, Ikeda K, et al. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation[J]. Diagn Microbiol Infect Dis, 2008,62 (3) : 292--297.
